Build status - In Progress
A Global Phase 2 Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of BMS-986177 an Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
Recruiting
99 years or below
All
Phase
2
15 participants needed
1 Location
Brief description of study
See full protocol for details.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
14 Oct 2020.
Study ID: 831974
Find a site
,
Your Information has been sent successfully.
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or